Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.

Autor: Douma LH; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., de Vries JF; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Smesseim I; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Baas P; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Schilder B; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Vermeulen M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Burgers JA; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: s.burgers@nki.nl., de Gooijer CJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Nov; Vol. 24 (11), pp. 1219-1228. Date of Electronic Publication: 2023 Oct 13.

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

Autor: Disselhorst MJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: m.disselhorst@nki.nl., Quispel-Janssen J; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., de Vries JF; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, Netherlands., Harms E; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Burgers S; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Baas P; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2019 Mar; Vol. 7 (3), pp. 260-270. Date of Electronic Publication: 2019 Jan 16.

New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.

Autor: van der Velden VH; Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., de Launaij D; Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., de Vries JF; Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., de Haas V; Dutch Childhood Oncology Group, The Hague, The Netherlands., Sonneveld E; Dutch Childhood Oncology Group, The Hague, The Netherlands., Voerman JS; Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., de Bie M; Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., Revesz T; Women's and Children's Hospital, Adelaide, South Australia, Australia., Avigad S; Molecular Oncology, Felsenstein Medical Research Centre, Paediatric Haematology Oncology, Tel Aviv University, Schneider Children's Medical Centre of Israel, Petah Tikva, Israel., Yeoh AE; Department of Paediatrics, Division of Haematology-Oncology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore, Singapore., Swagemakers SM; Department of Bioinformatics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands., Eckert C; Department of Paediatric Oncology/Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany., Pieters R; Dutch Childhood Oncology Group, The Hague, The Netherlands.; Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands., van Dongen JJ; Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Publikováno v: British journal of haematology [Br J Haematol] 2016 Mar; Vol. 172 (5), pp. 769-81. Date of Electronic Publication: 2015 Dec 21.

Relationship between molecular structure of cereal dietary fiber and health effects: focus on glucose/insulin response and gut health.

Autor: Gemen R; CSM Innovation, Diemen, The Netherlands., de Vries JF, Slavin JL

Publikováno v: Nutrition reviews [Nutr Rev] 2011 Jan; Vol. 69 (1), pp. 22-33.

Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis.

Autor: Csinady E; Children's Cancer Research Institute, Vienna, Austria., van der Velden VH, Joas R, Fischer S, de Vries JF, Beverloo HB, König M, Pötschger U, van Dongen JJ, Mann G, Haas OA, Panzer-Grümayer ER

Publikováno v: Leukemia [Leukemia] 2009 May; Vol. 23 (5), pp. 870-6. Date of Electronic Publication: 2009 Jan 15.